hNPC01 — the world's first iPSC-derived neural progenitor cell therapy for hemorrhagic stroke — demonstrates durable functional recovery with 2.5-year follow-up in the first patient and has obtained FDA IND approval for a Phase I/IIa trial.

💡 Key Milestones:
• First patient treated — 2.5-year follow-up shows durable functional recovery
• FDA IND approval — Phase I/IIa trial in the United States
• iPSC-derived neural progenitor cells (NPCs) — a first-in-class therapy for stroke
• Hemorrhagic stroke — addressing a major unmet clinical need with no approved regenerative therapies

Introduction

Hemorrhagic stroke accounts for approximately 10–15% of all strokes but contributes to a disproportionately high share of stroke-related morbidity and mortality. Unlike ischemic stroke, for which thrombolytic and endovascular therapies exist, hemorrhagic stroke has no approved regenerative therapy. Patients who survive the initial hemorrhage are often left with severe and permanent neurological deficits.

hNPC01 — a human iPSC-derived neural progenitor cell therapy developed by Hopstem Biotechnology — represents the first regenerative approach specifically designed for hemorrhagic stroke.

The hNPC01 Therapy

hNPC01 consists of neural progenitor cells (NPCs) derived from clinical-grade human induced pluripotent stem cells (iPSCs). These cells are designed to:

  • Differentiate into neurons and glial cells — replacing lost neural tissue in the stroke cavity
  • Secrete neurotrophic factors — promoting endogenous neurogenesis and reducing inflammation
  • Integrate into host neural circuits — potentially restoring lost function

First Patient: 2.5-Year Follow-Up

The first patient treated with hNPC01 underwent transplantation in a study conducted at the Chinese PLA General Hospital (301 Hospital), led by Professor Ying Zhe, Director of the Department of Neurosurgery.

Clinical outcomes at 2.5 years post-transplantation:

  • Durable functional improvement — sustained recovery in motor function
  • Favorable safety profile — no tumorigenicity, severe inflammation, or other safety concerns
  • Long-term engraftment — evidence of persistent cell survival and integration

FDA IND and Global Development

On July 2, 2025, Hopstem Biotechnology announced that the U.S. Food and Drug Administration (FDA) had approved the IND application for hNPC01, authorizing a Phase I/IIa clinical trial for the treatment of hemorrhagic stroke.

This makes hNPC01 the first human iPSC-derived cell therapy to receive FDA IND approval for the treatment of stroke, validating the quality, safety, and manufacturing standards of the China-developed iPSC platform.

Significance

  • First regenerative therapy for hemorrhagic stroke — no approved regenerative therapies currently exist
  • Longest follow-up to date — 2.5 years of durable efficacy data
  • Global regulatory validation — FDA IND approval demonstrates quality and safety standards
  • China-origin innovation — developed entirely in China, now going global
📌 Data sources: Hopstem Biotechnology, Chinese PLA General Hospital, FDA, and public announcements (2025–2026).